S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
NASDAQ:AVXL

Anavex Life Sciences (AVXL) Stock Price, News & Analysis

$3.78
-0.02 (-0.53%)
(As of 04/19/2024 ET)
Today's Range
$3.60
$3.80
50-Day Range
$3.78
$6.14
52-Week Range
$3.60
$10.45
Volume
2.08 million shs
Average Volume
1.12 million shs
Market Capitalization
$310.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00

Anavex Life Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
958.2% Upside
$40.00 Price Target
Short Interest
Bearish
26.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
0.08mentions of Anavex Life Sciences in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$374,972 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.57) to ($0.87) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.37 out of 5 stars

Medical Sector

285th out of 909 stocks

Biological Products, Except Diagnostic Industry

40th out of 149 stocks

AVXL stock logo

About Anavex Life Sciences Stock (NASDAQ:AVXL)

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

AVXL Stock Price History

AVXL Stock News Headlines

With the “Bitcoin Loophole” you can supercharge the gains by 10x or more
Thanks to this newly discovered Bitcoin Loophole, you can now trade Bitcoin in any regular brokerage account… And not only that… you can use it to supercharge the gains of Bitcoin by 10x or more! You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history. That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords…
Anavex Life Sciences Corp
With the “Bitcoin Loophole” you can supercharge the gains by 10x or more
Thanks to this newly discovered Bitcoin Loophole, you can now trade Bitcoin in any regular brokerage account… And not only that… you can use it to supercharge the gains of Bitcoin by 10x or more! You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history. That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords…
See More Headlines
Receive AVXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
4/21/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AVXL
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.00
High Stock Price Target
$40.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+958.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-47,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.73 per share

Miscellaneous

Free Float
72,588,000
Market Cap
$310.38 million
Optionable
Optionable
Beta
0.56
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Christopher U. Missling M.B.A. (Age 58)
    M.S., Ph.D., President, CEO, Secretary & Director
    Comp: $828.25k
  • Ms. Sandra Boenisch CPA (Age 43)
    CGA, Principal Financial Officer & Treasurer
    Comp: $194.36k
  • Mr. Stephan Toutain M.B.A. (Age 58)
    M.S., Senior VP of Operations & COO
  • Dr. Walter E. Kaufmann M.D.
    Chief Scientific Officer
  • Clint Tomlinson
    VP of Corporate
  • Dr. Adebayo Laniyonu Ph.D.
    Senior Vice President of Nonclinical Development
  • Dr. Edward R Hammond M.D.
    M.P.H., Ph.D., Chief Medical Officer
  • Dr. Kun Jin Ph.D.
    Head of Biostatistics
  • Mr. David Goldberger R.Ph.
    Senior Vice President of Regulatory Affairs

AVXL Stock Analysis - Frequently Asked Questions

Should I buy or sell Anavex Life Sciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVXL shares.
View AVXL analyst ratings
or view top-rated stocks.

What is Anavex Life Sciences' stock price target for 2024?

1 Wall Street analysts have issued 1-year price targets for Anavex Life Sciences' stock. Their AVXL share price targets range from $40.00 to $40.00. On average, they expect the company's stock price to reach $40.00 in the next twelve months. This suggests a possible upside of 958.2% from the stock's current price.
View analysts price targets for AVXL
or view top-rated stocks among Wall Street analysts.

How have AVXL shares performed in 2024?

Anavex Life Sciences' stock was trading at $9.31 at the start of the year. Since then, AVXL stock has decreased by 59.4% and is now trading at $3.78.
View the best growth stocks for 2024 here
.

Are investors shorting Anavex Life Sciences?

Anavex Life Sciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 22,120,000 shares, an increase of 10.6% from the March 15th total of 20,000,000 shares. Based on an average daily volume of 1,280,000 shares, the days-to-cover ratio is presently 17.3 days.
View Anavex Life Sciences' Short Interest
.

When is Anavex Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our AVXL earnings forecast
.

How were Anavex Life Sciences' earnings last quarter?

Anavex Life Sciences Corp. (NASDAQ:AVXL) posted its earnings results on Wednesday, February, 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04.

What ETF holds Anavex Life Sciences' stock?

iShares Neuroscience and Healthcare ETF holds 9,668 shares of AVXL stock, representing 1.85% of its portfolio.

What other stocks do shareholders of Anavex Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), LadRx (CYTR), SharkNinja (SN), Novavax (NVAX), Geron (GERN), VASCO Data Security International (VDSI), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

Who are Anavex Life Sciences' major shareholders?

Anavex Life Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.11%), Saxon Interests Inc. (0.03%) and Fiduciary Alliance LLC (0.02%). Insiders that own company stock include Athanasios Skarpelos, Christopher U Missling, Elliot Favus, Elliot Favus, Peter DO Donhauser and Sandra Boenisch.
View institutional ownership trends
.

How do I buy shares of Anavex Life Sciences?

Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVXL) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners